The Potential of DREADDs: A Game-Changer in Neuroscientific Research

DREADD neuroscience has transformed how researchers interrogate the living brain: a single stereotaxic injection of an AAV-packaged DREADD construct, followed by systemic delivery of a synthetic actuator, is now enough to activate or silence a precisely defined neuronal population for minutes to hours — with no implanted hardware and full reversibility. Chemogenetics using DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) has become the workhorse approach for dissecting the causal role of specific circuits in behavior, disease, and therapeutic intervention. This article covers the molecular design of DREADDs, their signaling mechanisms, AAV delivery strategies, a comparison with optogenetics, key research applications, and the DREADD vectors available from BioHippo.

What Is a DREADD? Background and Design

Designer Receptors Exclusively Activated by Designer Drugs are engineered G protein-coupled receptors (GPCRs) that have been mutated so they no longer respond to their natural ligand but gain sensitivity to an otherwise pharmacologically inert synthetic compound. The concept of receptors activated solely by synthetic ligands (RASSLs) dates to 1998, but the modern DREADD era began in 2007 when Armbruster et al. reported the first validated tool, hM3Dq, engineered from the human M3 muscarinic acetylcholine receptor by introducing two point mutations — Y3.33C and A5.46G in the Ballesteros–Weinstein GPCR numbering system — that abolished acetylcholine binding while conferring exquisite sensitivity to clozapine-N-oxide (CNO) (Armbruster et al., PNAS 2007).

The two principal DREADD classes used in neuroscience are:

• hM3Dq (excitatory DREADD): Derived from the human M3 muscarinic receptor; couples to Gq. CNO binding activates phospholipase C (PLC), raising inositol trisphosphate (IP₃) and diacylglycerol (DAG), releasing intracellular Ca²⁺, and depolarizing the neuron.
• hM4Di (inhibitory DREADD): Derived from the human M4 muscarinic receptor; couples to Gi. CNO binding inhibits adenylyl cyclase (reduces cAMP) and opens G protein-coupled inwardly rectifying potassium (GIRK) channels, hyperpolarizing and silencing the neuron.

A third class, the kappa-opioid receptor-based DREADD (KORD), was developed by Vardy et al. (2015) as an orthogonal inhibitory tool actuated by salvinorin B (SalB) rather than CNO, enabling dual-DREADD experiments in the same animal (Vardy et al., Neuron 2015). BioHippo stocks AAV vectors encoding both hM3Dq, hM4Di, and KORD constructs with multiple promoters and reporters — see the product section below.

How DREADDs Work: Signaling Mechanisms and Actuators

The original actuator for all muscarinic DREADDs is clozapine-N-oxide (CNO), the N-oxide derivative of the atypical antipsychotic clozapine. CNO was originally assumed to be pharmacologically inert at doses used for DREADD activation (0.1–5 mg/kg i.p. in rodents). However, a landmark 2017 study by Gomez et al. demonstrated that CNO undergoes back-metabolism to clozapine in vivo, and that behavioral effects attributed to DREADD activation could in some cases be explained by clozapine acting on endogenous receptors (Gomez et al., Cell Reports 2017). This finding prompted the development of improved actuators:

• Deschloroclozapine (DCZ): A next-generation DREADD agonist with approximately 1,000-fold higher potency than CNO at DREADDs, superior CNS penetration, and negligible back-metabolism to clozapine. DCZ is now the preferred actuator for in vivo behavioral studies, particularly in non-human primates (Nagai et al., Nature Neuroscience 2020).
• Perlapine and doxapram: Additional low-efficacy agonists with favorable pharmacokinetic profiles, used in specific experimental contexts.
• Salvinorin B (SalB): The specific actuator for KORD — does not activate hM3Dq or hM4Di, enabling orthogonal chemogenetic control in dual-DREADD experiments.

hM3Dq signaling in detail: CNO/DCZ → Gq activation → PLC-β → IP₃/DAG → IP₃-receptor-mediated Ca²⁺ release from the endoplasmic reticulum + PKC activation → membrane depolarization → increased action potential firing. This mimics the effect of excitatory neuromodulators and is used to activate specific circuits on demand.

hM4Di signaling in detail: CNO/DCZ → Gi activation → adenylyl cyclase inhibition → cAMP reduction + Gβγ-mediated GIRK channel opening → K⁺ efflux → membrane hyperpolarization → reduced or abolished firing. This is the most widely used approach to silence defined populations during behavioral tasks.

Delivery: AAV-Mediated DREADD Expression

DREADDs are genetic tools — they require stable delivery of the transgene to the target cell population. Adeno-associated virus (AAV) is the dominant delivery vehicle for DREADD neuroscience because of its safety profile, long-term stable expression, and the availability of serotypes and capsid variants with distinct tropism and CNS penetration characteristics.

The standard experimental workflow involves stereotaxic injection of an AAV-DREADD construct into a defined brain region. The most widely used constructs pair a neuronal promoter (hSyn for pan-neuronal expression; CaMKIIα for excitatory neurons; GFAP or GfaABC1D for astrocytes) with the DREADD receptor and a fluorescent reporter (mCherry or EGFP) for expression verification. For cell-type-specific targeting in transgenic Cre-driver mice or rats, Cre-dependent DIO/FLEX constructs are used: the DREADD transgene is inserted in inverted orientation flanked by incompatible lox sites and is only expressed after Cre-mediated recombination.

Key AAV capsid strategies for DREADD delivery:

• AAV2/5 and AAV2/9: The most commonly used serotypes for local stereotaxic injections in rodents; efficient transduction of cortical, striatal, and limbic circuits.
• AAV2/9 systemic delivery: Crosses the blood-brain barrier (BBB) in neonatal mice, enabling global CNS DREADD expression without surgery.
• AAV-PHP.eB: Engineered capsid with dramatically enhanced CNS penetration after intravenous injection in adult mice; ideal for brain-wide DREADD expression.
• rAAV2-retro (retrograde AAV): Engineered to travel retrogradely from the injection site to presynaptic neurons, enabling projection-specific DREADD targeting — e.g., infecting all neurons projecting into a nucleus of interest (Tervo et al., Neuron 2016).

All BioHippo DREADD AAV vectors are available across this full panel of serotypes, including PHP.eB, rAAV2-retro, and AAV2/9, on the same construct backbone — enabling researchers to select the optimal capsid for their experimental design without switching suppliers. Browse the full AAV vector collection.

DREADDs vs. Optogenetics: Choosing the Right Tool

DREADDs and optogenetics are complementary chemogenetic and optical approaches to controlling defined neuronal populations. The choice depends primarily on the temporal resolution required and the experimental context:

As reviewed by Sternson & Roth (2014), the two approaches are not competing but complementary: DREADDs are generally preferred for chronic behavioral studies and for experiments where hardware implantation would be confounding, while optogenetics remains the gold standard when millisecond-resolution circuit interrogation is required (Sternson & Roth, Annu Rev Neurosci 2014).

Research Applications of DREADDs

The versatility of the DREADD platform has made it applicable across virtually every domain of systems neuroscience and translational research:

• Feeding and energy homeostasis: hM3Dq activation of AgRP neurons in the arcuate nucleus drives robust hyperphagia — directly establishing causality between this circuit and hunger (Krashes et al., J Clin Invest 2011).
• Fear and anxiety: BLA (basolateral amygdala) excitation via hM3Dq in CaMKIIα-expressing neurons drives anxiety-like behavior; hM4Di silencing of BLA reduces fear expression in conditioned-fear paradigms.
• Addiction and reward: D1-MSN vs. D2-MSN dissection in nucleus accumbens using cell-type-specific DREADDs has clarified the bidirectional control of drug-seeking behavior.
• Parkinson's disease models: DREADD-mediated rescue of dopaminergic neuron activity in 6-OHDA or MPTP models has been used to validate circuit-level therapeutic strategies.
• Epilepsy: Inhibitory hM4Di constructs targeted to seizure foci or to GABAergic interneurons have demonstrated suppression of ictal activity in rodent models, with potential relevance to focal epilepsy therapy.
• Social behavior and memory: Hippocampal CA2 and medial prefrontal circuits involved in social memory have been probed with DREADDs to establish the necessity of specific cell populations for social recognition.
• Non-human primate research: DCZ-activated DREADDs have been successfully used in marmosets and macaques, where the higher potency and CNS penetration of DCZ is critical given the much larger brain volume relative to rodents.

Importantly, DREADDs remain a research tool only. No DREADD-based therapy has reached clinical use; however, the insights generated from DREADD experiments continue to drive the identification of therapeutic circuit targets and validate chemogenetic approaches that may eventually inform gene therapy strategies.

BioHippo DREADD Research Products

BioHippo stocks a comprehensive panel of ready-to-use AAV DREADD vectors spanning hM3Dq (excitatory, Gq-coupled), hM4Di (inhibitory, Gi-coupled), and KORD (inhibitory, kappa-opioid receptor-based) constructs. Every construct is available across 28+ AAV serotypes on the same plasmid backbone — from AAV2/1, 2/2, 2/5, 2/8, and 2/9, to engineered capsids including AAV-PHP.eB and rAAV2-retro. Promoter options span pan-neuronal (hSyn), excitatory-neuron-specific (CaMKIIα), astrocyte-specific (GFAP, GfaABC1D), GABAergic (VGAT1, GAD67), dopaminergic (TH), and inducible (TRE3G) systems. Both constitutive and Cre-dependent (DIO/FLEX and fDIO) configurations are available.

Selected DREADD vectors from BioHippo:

• AAV-hSyn-hM3D(Gq)-EGFP-WPRE (BHV12400085) — pan-neuronal excitatory DREADD, EGFP reporter, constitutive
• AAV-hSyn-DIO-hM3D(Gq)-mCherry-WPRE (BHV12400084) — Cre-dependent excitatory DREADD, mCherry reporter
• AAV-CaMKIIα-hM3D(Gq)-mCherry-WPRE (BHV12400091) — excitatory-neuron-specific hM3Dq
• AAV-hSyn-hM4D(Gi)-EGFP-WPRE (BHV12400069) — pan-neuronal inhibitory DREADD, constitutive
• AAV-hSyn-DIO-hM4D(Gi)-mCherry-WPRE (BHV12400068) — Cre-dependent inhibitory DREADD
• AAV-CaMKIIα-hM4D(Gi)-mCherry-WPRE (BHV12400066) — excitatory-neuron-specific hM4Di
• AAV-hSyn-dF-HA-KORD-IRES-mCitrine-WPRE (BHV12400082) — KORD inhibitory DREADD for orthogonal dual-DREADD experiments

All vectors are available from $397/100 µL at ≥2.00×10¹² vg/mL. Custom serotypes, titers, and packaging can be requested via the BioHippo quote request form. For questions about experimental design, promoter selection, or serotype choice for your target region, contact orders@biohippo.com.

Frequently Asked Questions

What is a DREADD?

A DREADD (Designer Receptor Exclusively Activated by a Designer Drug) is an engineered G protein-coupled receptor that has been mutated to be insensitive to its natural ligand (e.g., acetylcholine) but highly sensitive to a synthetic, otherwise pharmacologically inert compound such as clozapine-N-oxide (CNO) or deschloroclozapine (DCZ). DREADDs are introduced into specific neurons using viral vectors (typically AAV) and activated on demand by systemic injection of the actuator, allowing researchers to turn defined neuronal populations on or off in living animals.

How do DREADDs work?

DREADDs work by coupling to endogenous G protein signaling pathways. The excitatory DREADD hM3Dq couples to Gq: when the synthetic actuator binds, it activates phospholipase C, raises intracellular Ca²⁺, and depolarizes the neuron. The inhibitory DREADD hM4Di couples to Gi: actuator binding inhibits adenylyl cyclase and opens GIRK potassium channels, hyperpolarizing and silencing the cell. The effect lasts for the duration the actuator occupies the receptor — typically 30 minutes to 2 hours for CNO at standard doses, or up to several hours for DCZ at low nanomolar concentrations.

What is the difference between DREADDs and optogenetics?

The key difference between DREADDs and optogenetics is temporal resolution and hardware requirements. Optogenetics uses light-activated ion channels (opsins) delivered by AAV, with millisecond precision over neuronal firing but requiring an implanted fiber optic and laser system. DREADDs use a chemical actuator (CNO or DCZ) that is injected systemically, providing minutes-to-hours of modulation with no implanted hardware — making them better suited to chronic behavioral studies, large animals, and naturalistic experimental settings. Both tools require AAV delivery of the transgene and offer cell-type-specific targeting through promoter and Cre-dependent strategies.

What is clozapine N-oxide (CNO) and is it safe to use in vivo?

Clozapine N-oxide (CNO) is a synthetic compound derived from the antipsychotic clozapine and was the original actuator for DREADD experiments. CNO binds selectively to DREADD receptors at doses of 0.1–5 mg/kg i.p. in rodents. However, Gomez et al. (2017) showed that CNO undergoes back-metabolism to clozapine in vivo, raising the concern that some behavioral effects previously attributed to DREADD activation may partly reflect clozapine acting on endogenous dopamine and serotonin receptors. For this reason, many labs now prefer deschloroclozapine (DCZ), which is approximately 1,000× more potent at DREADDs, requires much lower doses, and has minimal back-metabolism. If CNO is used, the lowest effective dose and appropriate no-DREADD control animals are essential experimental controls.

How are DREADDs delivered to neurons?

DREADDs are delivered to neurons using adeno-associated virus (AAV) vectors. The DREADD transgene is packaged into an AAV plasmid under a cell-type-specific promoter (e.g., hSyn for all neurons, CaMKIIα for excitatory neurons, GFAP for astrocytes) and injected stereotaxically into the target brain region. For projection-specific targeting, retrograde AAV (rAAV2-retro) can be injected into a downstream nucleus to infect only presynaptic neurons that project there. For global brain-wide expression, high-CNS-penetrant capsids such as AAV-PHP.eB can be delivered intravenously. Expression typically reaches a stable level 2–4 weeks post-injection and can persist for months to years, making DREADDs practical for long-term behavioral studies.

References

1. Armbruster BN et al. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. PNAS. 2007;104(12):5163–5168.
2. Sternson SM, Roth BL. Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci. 2014;37:387–407.
3. Vardy E et al. A new DREADD facilitates the multiplexed chemogenetic interrogation of behavior. Neuron. 2015;86(4):936–946.
4. Gomez JL et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 2017;357(6350):503–507.
5. Krashes MJ et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest. 2011;121(4):1424–1428.
6. Tervo DGR et al. A designer AAV variant permits efficient retrograde access to projection neurons. Neuron. 2016;92(2):372–382.
7. Nagai Y et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nature Neuroscience. 2020;23:1157–1167.